2CB (Calithera Biosciences Inc) vs DAX Index Comparison

2CB

DAX Index

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

2CB

DAX Index

Difference

1Y 3Y 5Y 10Y 15Y 20Y

2CB

DAX Index

Add Stock

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

DAX Index

2CB

RYI

AVGR

BROG

Add Stock

1Y 3Y 5Y 10Y 15Y 20Y

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Calithera Biosciences Inc
Glance View

Market Cap

1m EUR

Industry

Biotechnology

Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. The company is headquartered in South San Francisco, California and currently employs 63 full-time employees. The company went IPO on 2014-10-02. The Company’s is engaged in discovering and development of targeted therapies, which disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. The firm is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients. The Company’s principal operations are based in South San Francisco, California. The company has a range of pipeline of small molecule drug candidates, which target enzymes controlling metabolically critical pathways in tumor cells and immune cells. The company has multiple internally discovered clinical stage compounds that are all enzyme inhibitors. The firm is engaged in developing telaglenastat in combination with standard therapies in a select set of solid tumors. Its lead development pathway for telaglenastat is for the treatment of KEAP1 or NRF2 mutated non-small cell lung cancer (NSCLC).

View 2CB Analysis

2CB Intrinsic Value

What is Intrinsic Value?

Economic Moat is a concept popularized by Warren Buffett to describe a company's durable competitive advantage. It represents the 'moat' that protects a company from competitors and helps it sustain profitability over the long term. Our analysis of the past 10 years showed that companies with a wide economic moat significantly outperformed the market, delivering +645% returns compared to +189% for the S&P 500.

Our research into Economic Moat performance spans the past 10 years and focuses on companies with a wide economic moat. For this analysis, we calculated the average stock price returns of these companies, comparing them to the performance of the S&P 500 index over the same period.

The results were compelling: wide moat stocks achieved a remarkable +645% average return, compared to +188% for the broader market. This difference highlights the long-term benefits of investing in businesses that can maintain their market position and pricing power over time.

Note: This research does not account for survivorship bias. Past performance is not indicative of future results.

Determining whether a company has an economic moat requires both a deep dive into financial metrics and a qualitative assessment of its competitive position. Our analysts conduct a rigorous evaluation that focuses on identifying structural advantages that enable a company to sustain profitability and defend its market share over the long term.

The process begins with an analysis of a company’s historical financial performance. We assess how consistently the company has generated returns above its cost of capital and whether those returns have been stable or improving. However, financial performance alone doesn’t reveal the full picture. To understand the sources of these advantages, we evaluate five key drivers of economic moats:

Network Effect: We analyze whether the value of a company’s product or service grows as its user base expands. Platforms like payment systems or marketplaces benefit from this self-reinforcing.

Switching Costs: We assess whether customers face significant costs or disruptions when switching to a competitor’s product or service. High switching costs create customer stickiness and provide pricing power.

Intangible Assets: Strong brands, patents, and regulatory licenses can protect a company’s market position by creating barriers for competitors or enabling premium pricing. For example, a well-recognized consumer brand may command higher customer loyalty and margins.

Efficient scale: Occurs when a market is optimally served by one or a few players, making it unprofitable for new entrants to compete. This typically happens in industries with high fixed costs or geographic constraints, such as utilities or pipelines.

Cost Advantage: Companies with structural cost advantages can produce goods or services at a lower cost than their competitors, enabling them to offer competitive pricing or maintain higher margins. These advantages often arise from economies of scale, superior supply chain management, or proprietary technology. Firms like Walmart leverage their massive scale to negotiate better terms with suppliers, allowing them to undercut competitors on price.

By examining these factors in combination with a company’s financial performance and market positioning, we classify each company into one of three categories:

This rigorous evaluation ensures that our moat ratings are both comprehensive and reliable, giving investors the tools they need to make well-informed, long-term decisions.

C
2CB

vs

D
DAX Index

Stocks Performance
2CB vs DAX Index

Performance Gap
2CB vs DAX Index

Performance By Year
2CB vs DAX Index

Competitors Performance
Calithera Biosciences Inc vs Peers

Calithera Biosciences Inc
Glance View

Company

Help

Tools

Stocks

C 2CB vs D DAX Index

Stocks Performance 2CB vs DAX Index

Performance Gap 2CB vs DAX Index

Performance By Year 2CB vs DAX Index

Competitors Performance Calithera Biosciences Inc vs Peers

Calithera Biosciences Inc Glance View

Company

Help

Tools

Stocks

C
2CB

vs

D
DAX Index

Stocks Performance
2CB vs DAX Index

Performance Gap
2CB vs DAX Index

Performance By Year
2CB vs DAX Index

Competitors Performance
Calithera Biosciences Inc vs Peers

Calithera Biosciences Inc
Glance View